Phase III Comparison of Adjuvant Chemotherapy with High-Dose Cyclophosphamide plus Doxorubicin (AC) versus Sequential Doxorubicin followed by Cyclophosphamide (A’C) in High-Risk Breast Cancer Patients with 0 - 3 Positive Nodes (Intergroup)

Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency

S Stecklein;W Barlow;L Pusztai;K Timms;R Kennedy;G Logan;R Seitz;S Badve;Y Gokmen-Polar;P Porter;H Linden;D Tripathy;G Hortobagyi;A Godwin;A Godwin;A Thompson;D Hayes;P Sharma JCO Precision Oncology Sep:7:e2300197. doi: 10.1200/PO.23.00197

PMid: PMID37972336 | PMC number: PMC10681491

Dual Classification by Immune Response Signature and Homologous Recombination Deficiency Reveals Immune-Dependent and -Independent Prognostic Groups in patients with Triple Negative Breast Cancer (TNBC) treated with AC Chemotherapy (SWOG S9313)

S Stecklein;W Barlow;L Pusztai;TBA Myriad;TBA Almac;S Badve;Y Gokmen-Polar;P Porter;H Linden;D Tripathy;G Hortobagyi;A Godwin;A Thompson;D Hayes;P Sharma San Antonio Breast Cancer Symposium (December 8-12, 2020, virtual), oral slide presentation

Validation of the DNA Damage Immune Response (DDIR) Signature in Triple-Negative Breast Cancer (TNBC) Patients from the SWOG 9313c Trial

P Sharma;W Barlow;A Godwin;E Parkes;L Knight;SM Walker;RD Kennedy;D Harkin;G Logan;CJ Steele;S Lambe;S Badve;Y Gokmen-Polar;H Pathak;K Isakova;HM Linden;P Porter;L Pusztai;AM Thompson;D Tripathy;G Hortobagyi;D Hayes Journal of Clinical Oncology Dec 20;37(36):3484-3492; Oct 28[Online ahead of print]

PMid: PMID31657982 | PMC number: PMC7194448

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313)

P Sharma;W Barlow;A Godwin;H Pathak;K Isakova;K Timms;A Hartman;R Wenstrup;H Linden;D Tripathy;G Hortobagyi;DF Hayes Annals of Oncology Mar 1;29(3):654-660; Dec 23 [Epub ahead of print] 2017

PMid: PMID29293876 | PMC number: PMC4076636

Impact of molecular subtypes on long term outcomes in triple negative breast cancer (TNBC) patients treated with adjuvant AC chemotherapy on SWOG S9313

P Sharma;W Barlow;D Hout;R Seitz;D Bailey;A Godwin;H Pathak;K Timms;C Solimeno;H Linden;P Porter;D Tripathy;G Hortobagyi;A Thompson;L Pusztai;D Hayes San Antonio Breast Cancer Symposium (Dec 4-8, 2018, San Antonio, TX), poster, P4-08-06

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

Impact of homologous recombination deficiency (HRD) biomarkers on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313)

P Sharma;W Barlow;A Godwin;H Pathak;K Isakova;AR Hartman;R Wenstrup;H Linden;D Tripathy;G Hortobagyi;D Hayes Proceedings of the American AACR Association for Cancer Research April 2017 Vol 58, abst. 1776 p. 456; AACR Annual Meeting (April 1-5, 2017, Washington, DC), poster

Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313)

P Sharma;W Barlow;A Godwin;L Knight;SM Walker;RD Kennedy;S Badve;Y Gokmen-Polar;H Pathad;S Isakova;H Linden;D Tripathy;G Hortobagyi;D Hayes J Clin Oncol 35, 2017 (suppl; abstr 529); American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster session

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

Modeling the relationship between progression-free survival and overall survival: the phase 2/3 trial

M Redman;B Goldman;M LeBlanc;A Schott;LH Baker Clinical Cancer Research, 19(10):2646-2656;

PMid: PMID23669424 | PMC number: PMC4131693

Multiplexed assessment of the Southwest Oncology Group directed intergroup breast cancer trial S9313 by AQUA show both high and low levels of HER2 are associated with poor outcome [PMC2843456; PMID20150438]

M Harigopal;W Barlow;G Tedeschi;P Porter;I Yeh;C Haskell;R Livingston;G Hortobagyi;G Sledge;C Shapiro;J Ingle;D Rimm;DF Hayes American Journal of Pathology 176(4):1639-1647;

Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status [PMC2734394; PMID19620488]

RR Tubbs;W Barlow;GT Budd;E Swain;P Porter;AM Gown;IT Yeh;G Sledge;S Shapiro;J Ingle;C Haskell;KS Albain;RB Livingston;DF Hayes Journal of Clinical Oncology, 27(24):3881-3886

Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous variable assessment

DL Rimm;M Harigopal;G Tedeschi;PL Porter;I-T Yeh;CM Haskell;W Barlow;RB Livingston;GN Hortobagyi;DF Hayes San Antonio Breast Cancer Symposium, abstract #75

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313) [PMID17308269]

HM Linden;CM Haskell;S Green;CK Osborne;GW Sledge;CL Shapiro;JN Ingle;D Lew;LF Hutchins;RB Livingston;S Martino Journal of Clinical Oncology 25(6):656-661

TOP2A gene amplification and response to adriamycin based therapy

RR Tubbs;W Barlow;GT Budd;E Swain;P Porter;I Yeh;G Sledge;C Shapiro;J Ingle;C Haskell;KS Albain;RB Livingston;DF Hayes San Antonio Breast Cancer Symposium #2005

p27Kip1 and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy

PL Porter;WE Barlow;IT Yeh;MG Lin;XP Yuan;E Donato;GW Sledge;CL Shapiro;JN Ingle;CM Haskell;KS Albain;JM Roberts;RB Livingston;DF Hayes Journal of the National Cancer Institute 98(23):1723-1731

Prognostic value of cell cycle regulators p27 and cyclin E: tissue microarray analysis of 1753 women enrolled in SWOG breast cancer trial 9313

PL Porter;W Barlow;IT Yeh;MG Lin;X Yuan;JN Ingle;CL Shapiro;GP Sledge;RB Livingston;DF Hayes Proc of the ASCO, JCO 23(16S):5s (#507)

Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by chyclophosphamide (A->C) in breast cancer patients with 0-3 positive nodes (Intergroup 0137)

CM Haskell;SJ Green;GW Sledge Jr;CL Shapiro;JN Ingle;D Lew;S Martino;R Livingston;CK Osborne Proc of the American Society of Clinical Oncology 21:36a(#142)